Travere Therapeutics Will Appoint New CEO in December
San Diego biopharma leaders should track this executive transition as the company prepares to shift its top-level management.
Updated on Sept. 21, 2026 in People
Live Poll
Does a planned CEO transition change how much you trust a public company's future performance?
San Diego-based Travere Therapeutics will appoint Bradley L. Campbell as president and chief executive officer on December 1, 2026. Campbell succeeds Eric Dube, who will step down after leading the firm since 2019.
Why it matters
The change follows Dr. Dube’s decision to prioritize his health and family, marking the end of an eight-year leadership tenure at the company. For operators, this transition represents a significant change in the firm's strategic oversight and executive leadership culture.
Incoming CEO Bradley L. Campbell brings over 25 years of biopharmaceutical experience to the role, following 20 years at Amicus Therapeutics where he became CEO in 2022. He assumes the position after Eric Dube’s 8-year tenure as president and CEO of the San Diego-based company.
The players
Bradley L. Campbell
An experienced biopharmaceutical executive who previously served as president and CEO of Amicus Therapeutics.
Eric Dube
The outgoing president and CEO of Travere Therapeutics who has led the organization since 2019.
Travere Therapeutics
A San Diego-based biopharmaceutical firm focused on the development of therapies for rare diseases.
The details
The board of directors initiated this leadership change following a formal search process to identify a successor. To ensure continuity during the shift, Dr. Dube will transition into an executive advisor role, a position he will hold until mid-February 2027 to assist with the handoff. Campbell will also join the company's board of directors upon assuming his new duties on the first of December.
Timeline
December 1, 2026: Bradley L. Campbell becomes president, CEO, and board member.
February 15, 2027: Eric Dube concludes his service as executive advisor.
Market Landscape
This leadership shift follows the pattern of the 2022 executive transition at Amicus Therapeutics, where Campbell previously served. The move highlights the common biopharma practice of recruiting seasoned CEOs from established firms to drive long-term growth and operational stability.
Operators in the biopharma sector should monitor how the new CEO recalibrates the firm's strategic focus after December 1. It is prudent to track whether this leadership change signals shifts in R&D investment priorities or partnership strategies within the local life sciences ecosystem.
The takeaway
Executive transitions at this scale often precede shifts in corporate strategy and resource allocation. Operators should monitor the company's official communications following December 1, 2026, for guidance on upcoming operational adjustments.
What happens next
Bradley L. Campbell will assume his position as president and CEO on December 1, 2026, with Eric Dube serving as executive advisor until February 15, 2027.
Further reading
For broader trends in regional management shifts, see People.
Live Poll
Does a planned CEO transition change how much you trust a public company's future performance?
